Brent Pfeiffenberger bought IPSC once, on Dec 12, 2025
President and CEO at Century Therapeutics, Inc.
SEC CIK 0002001162 · Filings on SEC.gov ↗
Brent Pfeiffenberger's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
1 filing since Dec 2025, newest first
About Brent Pfeiffenberger
Brent Pfeiffenberger, Pharm.D., MBA, is an individual corporate executive who serves as President and Chief Executive Officer of Century Therapeutics, Inc. (NASDAQ: IPSC) and a member of its Board, effective December 4, 2023.( Century Therapeutics is an innovative biotechnology company developing allogeneic, iPSC-derived cell therapies for autoimmune diseases and cancer.(
Dr. Pfeiffenberger brings more than 20 years of global experience in the healthcare and biopharmaceutical industries.( Before joining Century Therapeutics, he was Chief Operating Officer of Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca focused on cell therapies for cancer, and earlier spent nearly two decades at Bristol Myers Squibb in leadership roles including Senior Vice President, Head of U.S. Oncology and Co-Lead, Worldwide Commercial Oncology.( He began his career at Bristol Myers Squibb in roles spanning marketing, sales, market access and pricing, business development, and strategy and operations.( Dr. Pfeiffenberger earned a Pharm.D. from Duquesne University and an MBA from The Wharton School at the University of Pennsylvania.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.